Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
27 juin 2018 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Inc. Announces New CEO
12 juin 2018 08h32 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H....
Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
04 juin 2018 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors...
Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
14 mai 2018 09h05 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with...
Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
11 mai 2018 16h10 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
18 avr. 2018 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
04 avr. 2018 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today the presentation of a...
Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
29 mars 2018 08h10 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Present at Two International Conferences in March
09 mars 2018 08h30 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber,...
Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
08 mars 2018 08h30 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold...